Publications by authors named "Shalini Subramaniam"

Claim this Profile
C
Curability of metastatic cancer: a survey of medical oncologists.
Shalini Subramaniam, Kim Tam Bui, Martin R Stockler, Belinda E Kiely

JNCI Cancer Spectr· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.
Louise Emmett, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen

Lancet Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival and quality of life with [Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Anthony M Joshua, Shahneen Sandhu

Lancet Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab, Tremelimumab, and Platinum Chemotherapy in Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE).
Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, Chao-Hua Chiu, Antony J Mersiades

JTO Clin Res Rep· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical Oncologists.
Udit Nindra, Victoria Bray, Deme Karikios, Mohsen Shafiei, Shalini Subramaniam

Oncology· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients' perception of the benefits of palliative systemic therapy for advanced cancer.
Shalini Subramaniam, Diana H Adams, Annette Tognela, Felicia Roncolato, Po Y Yip

Intern Med J· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M Joshua

Lancet Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timing of prognostic discussions in people with advanced cancer: a systematic review.
Sharon H Nahm, Shalini Subramaniam, Martin R Stockler, Belinda E Kiely

Support Care Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel radionuclide therapy combinations in prostate cancer.
Andrisha-Jade Inderjeeth, Amir Iravani, Shalini Subramaniam, Ciara Conduit, Shahneen Sandhu

Ther Adv Med Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
'
'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501).
Dickon Hayne, Jeremy Grummet, David Espinoza, Steve P McCombie, Venu Chalasani, Shalini Subramaniam

BJU Int· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Louise Emmett, Shalini Subramaniam, Anthony M Joshua, Megan Crumbaker, Andrew Martin

BJU Int· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis